SCHEMBL25200779

SCHEMBL25200779

O=C(O)c1c(-c2cc(F)ccc2F)[nH]c2cc(Cl)ccc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
BLM P54132 1/20 0.45
KMT2A Q03164 1/20 0.45
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
GRIN3A Q8TCU5 1/20 0.41
PIM1 P11309 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
CSNK1G1 Q9HCP0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25215123 0.92 FEN1 (0.43) KDM4EMEN1LMNAHPGDMAPK1
SCHEMBL25235921 0.92 KDM4E (0.44) KDM4EMEN1LMNACYP2C9HPGD
SCHEMBL25199917 0.90 KDM4E (0.42) KDM4EMEN1KMT2ACA1CA2
SCHEMBL25193550 0.87 PTGES (0.39) KDM4E
SCHEMBL25197804 0.86 NR4A2 (0.48) CA9
SCHEMBL25209836 0.85 LMNA (0.49) KDM4EMEN1LMNACYP2C9HPGD
SCHEMBL25235907 0.84 ALDH1A1 (0.42) KDM4EMEN1HPGDKMT2A
SCHEMBL25199951 0.84 LMNA (0.48) KDM4EMEN1LMNACYP2C9HPGD
SCHEMBL25196072 0.81 KDM4E (0.46) KDM4EMEN1LMNACYP2C9HPGD
SCHEMBL25209824 0.81 KDM4E (0.45) KDM4ECLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271925-A1 NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ILAb Co., Ltd. (KR) 2023-08-31 US claimed
EP-4180423-A1 NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ILAb Co., Ltd. (KR) 2023-05-17 EP claimed
US-20230271925-A1 NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ILAb Co., Ltd. (KR) 2023-08-31 US disclosed
EP-4180423-A1 NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ILAb Co., Ltd. (KR) 2023-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271925-A1 NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TNF, NFKBIA, TNFRSF9 KDM4E 2857/4885MEN1 3757/4885LMNA 3926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.